ECSP21087299A - COMPOSITIONS AND METHODS FOR TREATING HEPATITIS C VIRUS - Google Patents

COMPOSITIONS AND METHODS FOR TREATING HEPATITIS C VIRUS

Info

Publication number
ECSP21087299A
ECSP21087299A ECSENADI202187299A ECDI202187299A ECSP21087299A EC SP21087299 A ECSP21087299 A EC SP21087299A EC SENADI202187299 A ECSENADI202187299 A EC SENADI202187299A EC DI202187299 A ECDI202187299 A EC DI202187299A EC SP21087299 A ECSP21087299 A EC SP21087299A
Authority
EC
Ecuador
Prior art keywords
virus
subject
methods
effective amount
amount
Prior art date
Application number
ECSENADI202187299A
Other languages
Spanish (es)
Inventor
Vahid Zia
Charles Reynolds
Darryl Cleary
Dimitrios Stefanidis
Reza Oliyai
Melissa Casteel
Robert Hindes
Miriam Berrey
Rowchanak Pakdaman
Hongmei Mo
William Symonds
Adrian Ray
Christy Hebner
Original Assignee
Gilead Pharmasset Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/055621 external-priority patent/WO2013040492A2/en
Priority claimed from US13/661,509 external-priority patent/US20130109647A1/en
Application filed by Gilead Pharmasset Llc filed Critical Gilead Pharmasset Llc
Publication of ECSP21087299A publication Critical patent/ECSP21087299A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En el presente documento se divulga una composición y forma de dosificación unitaria para el tratamiento de una infección causada por el virus de la hepatitis C (VHC) que comprende GS-7977 y al menos un excipiente farmacéuticamente aceptable, así como también los métodos para la fabricación de dicha composición y forma de dosificación unitaria. También en el presente documento se divulga un método para tratar a un sujeto, preferentemente un ser humano, infectado con el virus de la hepatitis C, dicho método comprende administrar al sujeto durante un período de tiempo una cantidad efectiva de GS-7977 y una cantidad efectiva de ribavirina. En un aspecto, el método comprende administrar al sujeto un régimen de tratamiento libre de interferón que comprende una cantidad efectiva de GS-7977 y una cantidad efectiva de ribavirina. En un aspecto particular, el método es suficiente para producir en el sujeto una cantidad indetectable de ARN del VHC durante al menos 12 semanas después de finalizado el período de tiempo.This document discloses a composition and unit dosage form for the treatment of an infection caused by the hepatitis C virus (HCV) comprising GS-7977 and at least one pharmaceutically acceptable excipient, as well as methods for the manufacture of said composition and unit dosage form. Also disclosed herein is a method of treating a subject, preferably a human, infected with hepatitis C virus, said method comprising administering to the subject over a period of time an effective amount of GS-7977 and an amount effective ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period.

ECSENADI202187299A 2011-11-29 2021-12-02 COMPOSITIONS AND METHODS FOR TREATING HEPATITIS C VIRUS ECSP21087299A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161564500P 2011-11-29 2011-11-29
PCT/US2012/055621 WO2013040492A2 (en) 2011-09-16 2012-09-14 Methods for treating hcv
US201261707459P 2012-09-28 2012-09-28
US13/661,509 US20130109647A1 (en) 2011-10-31 2012-10-26 Methods and compositions for treating hepatitis c virus

Publications (1)

Publication Number Publication Date
ECSP21087299A true ECSP21087299A (en) 2022-02-25

Family

ID=48803225

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202187299A ECSP21087299A (en) 2011-11-29 2021-12-02 COMPOSITIONS AND METHODS FOR TREATING HEPATITIS C VIRUS

Country Status (4)

Country Link
AP (1) AP2014007699A0 (en)
EC (1) ECSP21087299A (en)
IL (1) IL232889A (en)
MY (1) MY187735A (en)

Also Published As

Publication number Publication date
IL232889A (en) 2016-07-31
AP2014007699A0 (en) 2014-06-30
MY187735A (en) 2021-10-15
IL232889A0 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
ECSP14005678A (en) COMPOSITIONS AND METHODS TO TREAT HEPATITIS C VIRUS
AR088580A1 (en) METHODS AND COMPOSITIONS TO TREAT HEPATITIS C VIRUS
CL2021002747A1 (en) Antiviral Agents for Hepatitis B (Divisional Application No. 487-2020)
ECSP12012067A (en) HEPATITIS C VIRUS INHIBITORS
CO6592102A2 (en) Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
PH12019500289A1 (en) Vaccines directed against a human enteroviruses
ECSP14013315A (en) VIRAL APPLICATION INHIBITORS
EA201290575A1 (en) FLAVIVIRIDAE VIRUS INHIBITORS
EA201391519A1 (en) 2'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF THEIR USE FOR THE TREATMENT OF VIRAL DISEASES
MX384836B (en) ANTIVIRAL AGENTS AGAINST HEPATITIS B
EA201290576A1 (en) FLAVIVIRIDAE VIRUS INHIBITORS
MX2013000242A (en) TREATMENT OF DISEASES RELATED TO HEPATITIS C VIRUSES USING HYDROXYCLLOROQUINE OR A COMBINATION OF HYDROXYCLLOROQUINE AND AN ANTIVIRAL AGENT.
AR084237A1 (en) METHODS TO TREAT HEPATITIS C (HCV) VIRUSES, COMPOSITION
ECSP12011845A (en) NEW MACROCYCLIC INHIBITORS OF REPLICATION
CO6430434A2 (en) NEW COMPOSITIONS OF VACCINES WITH ACCELULAR PERTUSSIS AND MANUFACTURING METHOD OF THE SAME
GT201500046A (en) METHODS FOR THE TREATMENT OF HEPATITIS B AND HEPATITIS D INFECTIONS
UY33897A (en) HEPATITIS C VIRUS INHIBITORS
UY34066A (en) HEPATITIS C VIRUS INHIBITORS
MX2013013906A (en) Combined vaccines for prevention of porcine virus infections.
ECSP21087299A (en) COMPOSITIONS AND METHODS FOR TREATING HEPATITIS C VIRUS
PY1256476A (en) COMPOSITIONS AND METHODS FOR TREATING HEPATITIS C VIRUS
CR20140273A (en) COMPOSITIONS AND METHODS TO TREAT HEPATITIS C VIRUS
CL2014001397A1 (en) Pharmaceutical composition comprising a) gs-7977 and b) at least one pharmaceutically stable excipient; unit dosage form; composition preparation process; use of the composition to treat an infection caused by the hepatitis c virus.
CU20090188A7 (en) NEW INHIBITING PEPTIDES OF HEPATITIS C VIRUS REPLICATION
NI201400025A (en) VIRAL APPLICATION INHIBITORS